Appraising myc involvement in high risk myeloma

Leukemia and Lymphoma

Volumn 56, Issue 3, 2015, Pages 551-552

  Kastritis, Efstathios ^a   Dimopoulos, Meletios A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN; MYC PROTEIN; TUMOR MARKER;

CANCER RISK; CHROMOSOME 14; CHROMOSOME 14Q; CHROMOSOME 22; CHROMOSOME 8; CHROMOSOME REARRANGEMENT; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; KARYOTYPE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; NOTE; ONCOGENE C MYC; ONCOGENE MYC; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; FEMALE; GENETICS; MALE;

BIOMARKERS, TUMOR; CHROMOSOMES, HUMAN, PAIR 8; FEMALE; HUMANS; MALE; MULTIPLE MYELOMA; PROTO-ONCOGENE PROTEINS C-MYC;

EID: 84924750707     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.961015     Document Type: Note

References (11)

1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011;364:1046-1060.
2. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005;23:6333-6338.
3. Fonseca R, Bergsagel PL, Drach J, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009;23:2210-2221.
4. Walker BA, Wardell CP, Brioli A, et al. Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients. Blood Cancer J 2014;4:e191.
5. Affer M, Chesi M, Chen WD, et al. Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma. Leukemia 2014;28:1725-1735.
6. Glitza IC, Lu G, Shah R, et al. Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma. Leuk Lymphoma 2015;56:602-607.
7. Moreau P, Planche L, Attal M, et al. The combination of ISS 3, high LDH and t(4;14) and/or del(17p) identify a simple prognostic index for overall survival in patients treated with novel agents-based induction therapy and front-line autologous stem cell transplantation, and allow the definition of a subgroup of patients at high-risk of early death from progressive disease. Blood 2012;120(Suppl. 1) Abstract 598.
8. Holien T, Vatsveen TK, Hella H, et al. Addiction to c-MYC in multiple myeloma. Blood 2012;120:2450-2453.
9. Kuehl WM, Bergsagel PL. MYC addiction: a potential therapeutic target in MM. Blood 2012;120:2351-2352.
10. Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011;146:904-917.
11. Chaidos A, Caputo V, Gouvedenou K, et al. Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. Blood 2014;123:697-705.